Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.0%

2 terminated out of 40 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed with results

Key Signals

3 with results87% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (5)
Early P 1 (1)
P 1 (4)
P 2 (11)
P 3 (2)

Trial Status

Completed13
Unknown11
Recruiting11
Not Yet Recruiting3
Terminated2

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07209189Phase 2Recruiting

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT07532538Not Yet Recruiting

A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions

NCT06077643Recruiting

Workshops and Exchange Groups for Laryngectomized Patients

NCT07324317Not Yet RecruitingPrimary

Validation of End-to-End Difficult Airway Pathway Planning Algorithm (EAP-LC)

NCT02586207Phase 1Completed

Pembrolizumab in Combination With CRT for LA-SCCHN

NCT05894070RecruitingPrimary

The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer

NCT06761937Phase 1Recruiting

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

NCT05349487Not ApplicableCompletedPrimary

SpeakFree Heat and Moisture Exchanger (HME)

NCT06784401UnknownPrimary

Oncologic and Functional Outcome and Quality of Life in Patients Treated for Laryngeal Cancer

NCT05369234Phase 3Completed

Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis

NCT06611137Phase 2RecruitingPrimary

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

NCT06137378Phase 2Recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

NCT06554028Phase 2Not Yet RecruitingPrimary

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

NCT06308016RecruitingPrimary

Study of the Risk of Pharyngocutaneous Fistula in a Population of Patients Undergoing Total Laryngectomy and Creation of a Score for Pre-operative Risk Stratification.

NCT01332682Phase 1Completed

Resistance Training and Physical Functioning in Head and Neck Cancer Patients

NCT06024980Not ApplicableUnknownPrimary

Using the Subglottic Pressure to Predict the Dysphagia After Partial Laryngectomy

NCT01633541Phase 2CompletedPrimary

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

NCT05375266Recruiting

Immune Biomarker Study for Head and Neck Cancer

NCT05857202Unknown

Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer

Scroll to load more

Research Network

Activity Timeline